Fat as an endocrine organ: Relationship to the metabolic syndrome

American Journal of the Medical Sciences

Volumn 330, Issue 6, 2005, Pages 280-289

  Hutley, Louise ^a   Prins, Johannes B ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSINOGEN; AUTACOID; C REACTIVE PROTEIN; FAT; FATTY ACID; FIBRINOGEN; GLUCOCORTICOID; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAS PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADIPOSE TISSUE CELL; ANGIOGENESIS; ATHEROMATOSIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CHRONIC INFLAMMATION; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY THROMBOSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; ENDOCRINE GLAND; ENDOTHELIUM LESION; HEALTH CARE SYSTEM; HEART HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; REGULATORY MECHANISM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; VISCERA;

EID: 29244465117     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200512000-00005     Document Type: Conference Paper

References (186)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-8.
3. Forest C, Corvol P, Lazdunski M. New developments in metabolic syndrome. Biochimie 2005;87:1-3.
4. Pinhas-Hamie O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128:608-15.
5. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802-10.
6. Daniels SR, Arnett DK, Eckel RH, et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005;111:1999-2012.
7. Kohen-Avramoglu R, Theriault A, Adeli K. Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. Clin Biochem 2003;36:413-20.
8. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61.
9. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-8.
10. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999;892:146-54.
11. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104:531-43.
12. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-81.
13. Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol 2005;5:122-8.
14. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005;56:45-62.
15. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-70.
16. Greenfield JR, Campbell LV. Insulin resistance and obesity. Clin Dermatol 2004;22:289-95.
17. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
18. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity inflammation and atherogenesis. Endocrinology 2003;144:2195-200.
19. Caglayan E, Blaschke F, Takata Y, et al. Metabolic syndrome- interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 2005;5:135-42.
20. Maison P, Byrne CD, Hales CN, et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 2001;24:1758-63.
21. Lacquemant C, Vasseur F, Lepretre F, et al. Adipocytokins, obesity and development of type 2 diabetes. [French] Med Sci (Paris) 2003;19:809-17.
22. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
23. Hamdy O. Lifestyle modification and endothelial function in obese subjects. Expert Rev Cardiovasc Ther 2005;3:231-41.
24. Rabin KR, Kamari Y, Avni I, et al. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 2005;3:465-71.
25. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-55.
26. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998;395:763-70.
27. Farooqi IS, Keogh JM, Kamath S, et al. Partial leptin deficiency and human adiposity. Nature 2001;414:34-5.
28. Berg AH, Combs TP, Scherer PE . ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-9.
29. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
30. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
31. Uysal KT, Weisbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-4.
32. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
33. Banerjee RR, Rangwala SM, Shapiro JJ, et al. Regulation of fasted blood glucose by resistin. Science 2004;303:1195-8.
34. Karlsson C, Lindell K, Ottosson M, et al. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925-9.
35. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15:2727-9.
36. Vidal H. Gene expression in visceral and subcutaneous adipose tissues. Ann Med 2001;33:547-55.
37. Wang B, Jenkins JR, Trayhurn P . Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab 2005;288:E731-40.
38. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996;2:800-3.
39. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4.
40. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49.
41. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S25-8.
42. Matsuda M, Shimomura I. Adipocytokines and metabolic syndrome-molecular mechanism and clinical implication. [Japanese] Nippon Rinsho 2004;62:1085-90.
43. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995;270:26746-9.
44. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.
45. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996;221:286-9.
46. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117-21.
47. Staiger H, Kausch C, Guirguis A, et al. Induction of adiponectin gene expression in human myotubes by an adiponectin-containing HEK293 cell culture supernatant. Diabetologia 2003;46:956-60.
48. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004;35:842-9.
49. Nawrocki AR, Scherer PE. The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol 2004;4:281-9.
50. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
51. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 2004;53 Suppl 1:S143-51.
52. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications fpr metabolic regulation and bioactivity. J Biol Chem 2003;278:9073-85.
53. Wang Y, Xu A, Knight C, et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin: potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002;277:19521-9.
54. Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005;280:18073-80.
55. Rajala MW, Scherer PE. Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-73.
56. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
57. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003;46:1594-603.
58. Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108:1875-81.
59. Berg AH, Lin Y, Lisanti MP, et al. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am J Physiol Endocrinol Metab 2004;287:E1178-88.
60. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318-23.
61. Ryo M, Nakamura T, Kihana S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-81.
62. Schulze MB, Rimm EB, Shai I, et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004;27:1680-7.
63. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003;88:3236-40.
64. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-75.
65. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004;89:2697-703.
66. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 2000;97:14478-83.
67. Shibata R, Ouchi N, Kihara S, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004;10:1384-9.
68. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
69. Shibata R, Ouchi N, Kihara S, et al. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem 2004;279:28670-4.
70. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004;94:e27-31.
71. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem 2003;278:40352-63.
72. Qi Y, Takahashi N, Hileman SM, et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004;10:524-9.
73. Tsao TS, Thomas E, Murray HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity: different oligomers activate different signal transduction pathways. J Biol Chem 2003;278:50810-7.
74. Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-50.
75. Wang Y, Lam KS, Xu JY, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005;280:18341-7.
76. Iwashima Y, Katsuya T, Ishikawa K, et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005;45:1094-100.
77. Hattori Y, Akimoto K, Gross SS, et al. Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 2005.
78. Milewicz A, Zatonska K, Demissie M, et al. Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol 2005;20:68-73.
79. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
80. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
81. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8.
82. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995;83:1263-71.
83. Tartaglia LA. The leptin receptor. J Biol Chem 1997;272:6093-6.
84. Lynn RB, Cao GY, Considine RV, et al. Autoradiographic localization of leptin binding in the choroid plexus of ob/ob and db/db mice. Biochem Biophys Res Commun 1996;219:884-9.
85. White DW, Kuropatwinski KK, Devos R, et al. Leptin receptor (OB-R) signaling: cytoplasmic domain mutational analysis and evidence for receptor homo-oligomerization. J Biol Chem 1997;272:4065-71.
86. Zigman JM, Elmquist JK. Minireview: From anorexia to obesity-the yin and yang of body weight control. Endocrinology 2003;144:3749-56.
87. Wang Y, Kuropatwinski KK, White DW, et al. Leptin receptor action in hepatic cells. J Biol Chem 1997;272:16216-23.
88. Serradeil-Le Gal C, Raulaste D, Brossard G, et al. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett. 1997;404:185-91.
89. Hoggard N, Mercer JG, Rayner DV, et al. Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridization. Biochem Biophys Res Commun 1997;232:383-7.
90. Cao GY, Considine RV, Lynn RB. Leptin receptors in the adrenal medulla of the rat. Am J Physiol 1997;273:E448-52.
91. Walder K, Filippis A, Clark S, et al. Leptin inhibits insulin binding in isolated rat adipocytes. J Endocrinol 1997;155:R5-7.
92. Karlsson C, Lindell K, Svensson E, et al. Expression of functional leptin receptors in the human ovary. J Clin Endocrinol Metab 1997;82:4144-8.
93. Lostao MP, Urdaneta E, Martinez-Anso E, et al. Presence of leptin receptors in rat small intestine and leptin effect on sugar absorption. FEBS Lett 1998;423:302-6.
94. Wang MY, Zhou YT, Newgard CD, et al. A novel leptin receptor isoform in rat. FEBS Lett 1996;392:87-90.
95. Kieffer TJ, Heller RS, Habener JF. Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun 1996;224:522-7.
96. Emilsson V, Liu YL, Cawthorne MA, et al. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997;46:313-6.
97. El-Haschimi K, Pierroz DD, Hileman SM, et al. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000;105:1827-32.
98. Bjorbaek C, Elmquist JK, Michl P, et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998;1:619-25.
99. Shamsuzzaman AS, Winnicki M, Wolk R, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004;109:2181-5.
100. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-43.
101. Asilmaz E, Cohen P, Miuyazaki M, et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J Clin Invest 2004;113:414-24.
102. Huang W, Dedousis N, Bhatt BA, et al. Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. J Biol Chem 2004;279:21695-700.
103. Reilly MP, Iqbal N, Schutta M, et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004;89:3872-8.
104. Correia ML, Haynes WG. Obesity-related hypertension: is there a role for selective leptin resistance? Curr Hypertens Rep 2004;6:230-5.
105. Schafer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004;24:112-7.
106. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003;108:754-9.
107. O'Rahilly S, Farooqi IS, Yeo GS, et al. Minireview: human obesity-lessons from monogenic disorders. Endocrinology 2003;144:3757-64.
108. Montague CT, Farooqi IS, Whitehead JP, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-8.
109. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-84.
110. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
111. Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:R1-8.
112. Kralisch S, Klein J, Lossner U, et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005.
113. Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme 11 beta-hydroxysteroid dehydrogenase type 1(11 beta-HSD1) - a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2003;3 (4):255-62.
114. Morton NM, Patterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931-8.
115. Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-7.
116. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-3.
117. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11 Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A 1997;94:14924-9.
118. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-29.
119. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-8.
120. Wyne KL. Free fatty acids and type 2 diabetes mellitus. Am J Med 2003;115 Suppl 8A:29S-36S.
121. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004;20:295-304.
122. Cnop M, Hannaert JC, Hoorens A, et al. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes 2001;50:1771-7.
123. Lupi R, Dotta A, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002;51:1437-42.
124. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 2003;100:3077-82.
125. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003;65:333-47.
126. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S6-11.
127. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94:4318-23.
128. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997;94:4312-7.
129. Chiu HC, Kovacs A, Blanton RM, et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005;96:225-33.
130. Jouven X, Charles MA, Desnos M, et al. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation 2001;104:756-61.
131. Shankar SS, Steinberg HO. FFAs: do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 2005;5:30-5.
132. Rudin E, Barzilai N. Inflammatory peptides derived from adipose tissue. Immun Ageing 2005;2:1.
133. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004;14:228-32.
134. Tsigos C, Kyrou I, Chala E, et al. Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999;48:1332-5.
135. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50.
136. Stephens JM, Pekala PH. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulation is coordinate and independent of protein synthesis. J Biol Chem 1992;267:13580-4.
137. Banks RE, Forbes MA, Storr M, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995;102:217-23.
138. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996;97:2152-7.
139. Bullo M, Garcia-Lorda P, Megias I, et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003;11:525-31.
140. Kappes A, Loffler G. Influences of ionomycin, dibutyrylcycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res. 2000;32:548-54.
141. Maeda N, Takahashi M, Funahashi T, et al. PPAR-gamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
142. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12:180-6.
143. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212-7.
144. Weisberg SP, McCann D, Deasi M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
145. Xu H, Uysal KT, Becherer JD, et al. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 2002;51:1876-83.
146. Hauner H, Petruschke T, Russ M, et al. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995;38:764-71.
147. Zinman B, Hanley AJ, Harris SB, et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999;84:272-8.
148. Porter MH, Cutchins A, Fine JB, et al. Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Lab Clin Med 2002;139:140-6.
149. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96:3042-7.
150. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003;27 Suppl 3:S53-5.
151. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 2002;277:12364-8.
152. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004;50:1040-50.
153. Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest 2004;34:641-2.
154. Ritchie SA, Ewart MA, Perry CG, et al. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004;107:519-32.
155. Wallenius V, Wallenius K, Sunter D, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8:75-9.
156. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
157. Podor TJ, Jink FR, Loskutoff DJ, et al. Human endothelial cells produce IL-6. Lack of responses to exogenous IL-6. Ann N Y Acad Sci 1989;557:374-85; discussion 386-7.
158. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145:2273-82.
159. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
160. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51.
161. Bhakdi S, Torzewski M, Klouche M, et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999;19:2348-54.
162. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
163. Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-9.
164. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005;146:3417-27.
165. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004;53:1060-7.
166. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-84.
167. Wernstedt I, Eriksson AL, Berndtsson A, et al. A common polymorphism in the interleukin-6 gene promoter is associated with overweight. Int J Obes Relat Metab Disord 2004;28:1272-9.
168. Steensberg A. The role of IL-6 in exercise-induced immune changes and metabolism. Exerc Immunol Rev 2003;9:40-7.
169. Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med 2004;14:196-202.
170. De Pergola G, Pannacciulli N . Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002;25:899-904.
171. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005;5:149-54.
172. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998;18:1-6.
173. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004;28:1357-64.
174. Hoekstra T, Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004;91:861-72.
175. Sakata T, Mannami T, Baba S, et al. Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries. Atherosclerosis 2004;176:355-60.
176. Pantanetti P, Garrapa GG, Mantero F, et al. Adipose tissue as an endocrine organ? A review of recent data related to cardiovascular complications of endocrine dysfunctions. Clin Exp Hypertens 2004;26:387-98.
177. Janke J, Engeli S, Gorzelniak K, et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002;51:1699-707.
178. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003;4:43-55.
179. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807-25.
180. Boustany CM, Bharadwaj K, Daugherty A, et al. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004;287:R943-9.
181. Abdollahi MR, Gaunt TR, Syddall HE, et al. Angiotensin II type I receptor gene polymorphism: anthropometric and metabolic syndrome traits. J Med Genet 2005;42:396-401.
182. Tham DM, Martin-McNulty B, Wang YX, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002;11:21-30.
183. Emanueli C, Madeddu P. Renin-angiotensin and kallikrein-kinin systems coordinately modulate angiogenesis. Hypertension 2002;39:e29.
184. Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997;138:1512-9.
185. Malik FS, Lavie CJ, Mehra MR, et al. Renin-angiotensin system: genes to bedside. Am Heart J 1997;134:514-26.
186. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-8.